Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
July 26 2022 - 4:15PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease (AD), today announced
that the company will participate in the following upcoming
conferences:
- The Alzheimer’s Association
International Conference (AAIC), in San Diego and virtually, from
Sunday, July 31, to Thursday, August 4, 2022
- Acumen scientists will present a poster, “Preparation and
qualification of soluble amyloid beta oligomers for use in
bioanalytic assays supporting Alzheimer’s disease therapeutics,”
(P4-178) on August 3
- The BTIG Biotech Conference, in
New York and virtually, on Monday, August 8, 2022 at 2:00 pm ET
- Dr. Eric Siemers, Chief Medical
Officer, will be participating in an AD panel: “The Next Generation
of Anti-Amyloid and Anti-Tau Targeting Therapeutics for Alzheimer's
Disease”
About Acumen Pharmaceuticals,
Inc.Acumen Pharmaceuticals, headquartered in
Charlottesville, Va. with clinical operations based in Carmel,
Ind., is a clinical stage biopharmaceutical company developing a
novel disease-modifying approach to treat Alzheimer’s disease.
Acumen’s scientific founders pioneered research on toxic soluble
AβOs, which a growing body of evidence indicates are primary
triggers of Alzheimer’s disease pathology. Acumen is currently
focused on advancing its investigational product candidate, ACU193,
a humanized monoclonal antibody that selectively targets toxic
soluble AβOs in a Phase 1 clinical trial involving early
Alzheimer’s disease patients. For more information, visit
www.acumenpharm.com.
Contacts:
Media:AcumenPR@westwicke.com
Investors:investors@acumenpharm.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024